Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration
Genetic Engineering & Biotechnology News
|
May 16, 2023
X min read
Genetic Engineering & Biotechnology News
|
May 16, 2023
Share on Social
More like this
News
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
March 7, 2025
Read Now
Press
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
March 7, 2025
Read Now
